Press Releases

NEW YORK , July 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2018 financial results prior

NEW YORK , June 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the

Worldwide Ocaliva net sales of $35.2 million in the first quarter of 2018 2018 worldwide Ocaliva net sales currently expected to be between $170 million and $185 million Continuing to advance leading NASH Phase 3 program: REGENERATE trial in non-cirrhotic NASH patients with liver fibrosis on track

NEW YORK , May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior

NEW YORK , April 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its Board of Directors has appointed

11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA) NEW YORK , April 13, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and

NEW YORK , April 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has priced its upsized underwritten

NEW YORK , April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public

NEW YORK , March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the

Late-breaking presentation will feature the first clinical data from a biopsy-based substudy supporting obeticholic acid’s ability to reverse or stabilize fibrosis and cirrhosis in primary biliary cholangitis (PBC) patients NEW YORK , March 23, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals,